HMGCR loss is synthetic lethal with PIK3CD inhibition in colorectal cancer cells

Figure 1 HMGCR loss is synthetic lethal with PIK3CD inhibition in colorectal cancer cells. A: As indicated in the SOLAD, CSSL and SynLethDB online databases, HMGCR is synthetic lethal with PIK3CD in colorectal cancer (CRC); B: Cell Counting Kit-8 (CCK-8) results show that gefitinib enhanced the toxicity of CRC SW480 and HCT116 cells, and cell viability decreased in a concentration-dependent manner; C: CCK-8 results show that atorvastatin enhanced the toxicity of CRC SW480 and HCT116 cells, and cell viability decreased in a concentration-dependent manner; D and E: Clone formation assay showed that gefitinib or atorvastatin alone can enhance the toxicity of CRC SW480; F and G: HMGCR depletion significantly attenuated the anti-proliferative effects of the gefitinib-atorvastatin combination in both cell lines; H and I: Compared with atorvastatin or gefitinib alone, the combination of atorvastatin and gefitinib increased inhibition of the activity of SW480 cells and HCT116 cells; J: 5-ethynyl-2'-deoxyuridine assay revealed that compared with atorvastatin or gefitinib alone, the combination of atorvastatin and gefitinib increased inhibition of the activity of SW480 cells and HCT116 cells. Data are presented as the mean ± SD. ^aP < 0.001, ^bP < 0.01. OD: Optical density.